Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELIVATE
2019-002324-32Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tropifexor and licogliflozin in metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis (4 arms), sponsored by Novartis. Primary endpoint: Fibrosis improvement without worsening of steatohepatitis. Started Oct 2019; status: completed.
02
Drugs
tropifexorlicogliflozin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosis
Beyond the preview
Go deeper on 2019-002324-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002324-32.